AIDS Healthcare Foundation (AHF) has quietly reinstated funding to a Louisiana AIDS advocacy event, two weeks after pulling their support because one of its organizers is involved in a whistleblower lawsuit against AHF. And they really mean it this time -- and would prefer that we believe the withdrawal of support never happened.
The AIDS Healthcare Foundation scandal has taken a downright creepy turn.
Only one day after a stunning whistleblower lawsuit against AIDS Healthcare Foundation (AHF) was made public, the embattled organization withdrew funding from an upcoming HIV advocacy event because one of the plaintiffs is involved in its planning, according to records obtained by My Fabulous Disease.
Michael Weinstein, the polarizing and famously litigious head of AIDS Healthcare Foundation (AHF) just got a taste of his own medicine when a stunning Whistleblower lawsuit against AHF filed last year was unsealed and made public.
The annual HIV Cruise Retreat, commonly referred to as "The Poz Cruise," will set sail this November 8-15 aboard the Ruby Princess, departing Los Angeles and cruising the Mexican Riviera cities of Mazatlan, Puerto Vallarta and Cabo San Lucas.
The lobby of the Melbourne convention center at the international AIDS conference last July was packed with scientists, community educators, and activists. I was busy wrangling interviews for my daily video blogs.
Across the room I spotted JoAnne Keatley and Laxmi Narayan Tripathi, two of the most visible transgender women in the world and experts on transgender issues. I scurried up to them for a sound bite on their thoughts about the conference.
The first time I contracted gonorrhea, which in my day was affectionately called The Clap, I was 20 years old and had just moved to West Hollywood, California. It was 1981, disco was still thumping in the bars, and the bath houses were packed. My dance card was filled.
When Mary E. Bowman stepped to the stage five years ago at SpitDat, an open mic night in Washington, D.C., she was 20 years old and terrified. She was about to perform "Dandelions," her first poem to reveal a secret that her own family had long kept quiet: that Mary had lived with HIV since birth, the result of a mother addicted to drugs who died when Mary was only three.
They come from different cultures and regions of the world, but these fifteen HIV activists all share one important trait: a fierce devotion to HIV issues and a commitment to leave their mark on 2015.
By now the more scientific highlights from the 20th International AIDS Conference (AIDS 2014) in Melbourne has been digested and shared through your networks. There's always something unexpected -- and sometimes even encouraging, such as the new iPrEx study results showing, again, the efficacy of Truvada as pre-exposure prophylaxis (PrEP). The evidence mounts.
This week, Gilead was targeted by hepatitis C treatment activists over the stunning price of its new hepatitis C drug, sofosbuvir (Sovaldi): US$1,000 per pill for each day of a 12-week regimen. Because the medication is both more effective and offers a shorter treatment period than previous therapies, activists see the drug as key to ending the hepatitis C scourge as we know it -- but warn that the price could keep that from happening. They took action here at the conference, and one of those events is in this video.